BioCentury | Sep 1, 2014
Financial News

Med BioGene proposes private placement of units

Med BioGene Inc. (TSX-V:MBI), Vancouver, B.C. Business: Diagnostic, Pharmacogenetics Date announced: 2014-08-15 Type: Private placement of units To be raised: C$200,000 ($183,740) Units: 4 million Price: C$0.05 (unit) Shares outstanding prior: 79.9 million Note: Each...
BioCentury | Mar 31, 2014
Clinical News

GeneFx Lung regulatory update

...who are at higher and lower risks of mortality following surgical removal of their tumor. Med BioGene...
...in "further dialogue" with payers before launching the test. Precision has exclusive, worldwide rights from Med BioGene...
...develop and commercialize GeneFx Lung under an April 2011 deal (see BioCentury, April 18, 2011). Med BioGene Inc....
BioCentury | Mar 31, 2014
Clinical News

GeneFx Lung diagnostic data

...A validation study analyzing 181 frozen, resected stage I/II NSCLC tumor specimens showed that Med BioGene's GeneFx...
...SCC) cases (p=0.045). Data were published in the Journal of Thoracic Oncology. On March 24, Med BioGene...
...said Precision Therapeutics received U.S. approval to perform GeneFx Lung testing in its CLIA-certified laboratory. Med BioGene...
BioCentury | Sep 9, 2013
Company News

Med BioGene diagnostic news

...Diagnostic company Med BioGene said four shareholders discontinued a petition against the company that was filed in...
...Advance Notice Policy by the board in advance of the May 17 annual general meeting; Med BioGene's...
...meeting by the chairman. Med BioGene could not be reached for details (see BioCentury, June 17). Med BioGene's...
BioCentury | Sep 2, 2013
Company News

Med BioGene, Precision Therapeutics, Signal Genetics LLC diagnostic news

...estoppel remained. Signal was seeking judgment requiring Med BioGene to grant Signal an exclusive license to Med BioGene's...
...low-risk prognostic groups based on the molecular profile of a patient's tumor. On June 3, Med BioGene...
...reached for details (see BioCentury, Feb. 21, 2011; March 7, 2011 & March 4, 2013). Med BioGene Inc....
BioCentury | Jun 17, 2013
Company News

Med BioGene diagnostic news

...Diagnostic company Med BioGene said that four shareholders filed a petition in the British Columbia Supreme Court...
...Advance Notice Policy by the board in advance of the May 17 annual general meeting; Med BioGene's...
...person as directors of the company; and decisions made at the meeting by the chairman. Med BioGene...
BioCentury | Jun 3, 2013
Financial News

Med BioGene completes warrant exercise

Med BioGene Inc. (TSX-V:MBI), Vancouver, B.C. Business: Diagnostic, Pharmacogenetics Date completed: 5/24/13 Type: Warrant exercise Raised: C$231,798 (US$224,612) Shares: 2.3 million Price: C$0.10 Shares after offering: 79.9 million Investors: Existing investors WIR Staff Diagnostic...
BioCentury | Mar 4, 2013
Company News

Med BioGene, Precision Therapeutics, Signal Genetics LLC diagnostic news

...equitable estoppel. Signal is seeking judgment requiring Med BioGene to grant Signal an exclusive license to Med BioGene's...
...Med BioGene and alleged that Med BioGene committed fraud and that Precision committed tortious interference. Signal said Med BioGene...
...name of Signal's commercialization partner, which Med BioGene then disclosed to Precision. Signal requested judgment requiring Med BioGene...
BioCentury | Feb 6, 2012
Financial News

Med BioGene withdraws follow-on

...Inc. (TSX-V:MBI), Vancouver, B.C. Business: Diagnostic, Pharmacogenetics Date announced: 2/2/12 Type: Follow-on Underwriter: Rodman Note: Med BioGene...
BioCentury | May 23, 2011
Financial News

Med BioGene completes private placement of units

Med BioGene Inc. (TSX-V:MBI), Vancouver, B.C. Business: Diagnostic, Pharmacogenetics Date completed: 5/19/11 Type: Private placement of units Raised: C$210,000 (US$216,489) Units: 4.2 million Price: C$0.05 (unit) Shares after offering: 77.5 million Note: Each unit comprises...
Items per page:
1 - 10 of 27
BioCentury | Sep 1, 2014
Financial News

Med BioGene proposes private placement of units

Med BioGene Inc. (TSX-V:MBI), Vancouver, B.C. Business: Diagnostic, Pharmacogenetics Date announced: 2014-08-15 Type: Private placement of units To be raised: C$200,000 ($183,740) Units: 4 million Price: C$0.05 (unit) Shares outstanding prior: 79.9 million Note: Each...
BioCentury | Mar 31, 2014
Clinical News

GeneFx Lung regulatory update

...who are at higher and lower risks of mortality following surgical removal of their tumor. Med BioGene...
...in "further dialogue" with payers before launching the test. Precision has exclusive, worldwide rights from Med BioGene...
...develop and commercialize GeneFx Lung under an April 2011 deal (see BioCentury, April 18, 2011). Med BioGene Inc....
BioCentury | Mar 31, 2014
Clinical News

GeneFx Lung diagnostic data

...A validation study analyzing 181 frozen, resected stage I/II NSCLC tumor specimens showed that Med BioGene's GeneFx...
...SCC) cases (p=0.045). Data were published in the Journal of Thoracic Oncology. On March 24, Med BioGene...
...said Precision Therapeutics received U.S. approval to perform GeneFx Lung testing in its CLIA-certified laboratory. Med BioGene...
BioCentury | Sep 9, 2013
Company News

Med BioGene diagnostic news

...Diagnostic company Med BioGene said four shareholders discontinued a petition against the company that was filed in...
...Advance Notice Policy by the board in advance of the May 17 annual general meeting; Med BioGene's...
...meeting by the chairman. Med BioGene could not be reached for details (see BioCentury, June 17). Med BioGene's...
BioCentury | Sep 2, 2013
Company News

Med BioGene, Precision Therapeutics, Signal Genetics LLC diagnostic news

...estoppel remained. Signal was seeking judgment requiring Med BioGene to grant Signal an exclusive license to Med BioGene's...
...low-risk prognostic groups based on the molecular profile of a patient's tumor. On June 3, Med BioGene...
...reached for details (see BioCentury, Feb. 21, 2011; March 7, 2011 & March 4, 2013). Med BioGene Inc....
BioCentury | Jun 17, 2013
Company News

Med BioGene diagnostic news

...Diagnostic company Med BioGene said that four shareholders filed a petition in the British Columbia Supreme Court...
...Advance Notice Policy by the board in advance of the May 17 annual general meeting; Med BioGene's...
...person as directors of the company; and decisions made at the meeting by the chairman. Med BioGene...
BioCentury | Jun 3, 2013
Financial News

Med BioGene completes warrant exercise

Med BioGene Inc. (TSX-V:MBI), Vancouver, B.C. Business: Diagnostic, Pharmacogenetics Date completed: 5/24/13 Type: Warrant exercise Raised: C$231,798 (US$224,612) Shares: 2.3 million Price: C$0.10 Shares after offering: 79.9 million Investors: Existing investors WIR Staff Diagnostic...
BioCentury | Mar 4, 2013
Company News

Med BioGene, Precision Therapeutics, Signal Genetics LLC diagnostic news

...equitable estoppel. Signal is seeking judgment requiring Med BioGene to grant Signal an exclusive license to Med BioGene's...
...Med BioGene and alleged that Med BioGene committed fraud and that Precision committed tortious interference. Signal said Med BioGene...
...name of Signal's commercialization partner, which Med BioGene then disclosed to Precision. Signal requested judgment requiring Med BioGene...
BioCentury | Feb 6, 2012
Financial News

Med BioGene withdraws follow-on

...Inc. (TSX-V:MBI), Vancouver, B.C. Business: Diagnostic, Pharmacogenetics Date announced: 2/2/12 Type: Follow-on Underwriter: Rodman Note: Med BioGene...
BioCentury | May 23, 2011
Financial News

Med BioGene completes private placement of units

Med BioGene Inc. (TSX-V:MBI), Vancouver, B.C. Business: Diagnostic, Pharmacogenetics Date completed: 5/19/11 Type: Private placement of units Raised: C$210,000 (US$216,489) Units: 4.2 million Price: C$0.05 (unit) Shares after offering: 77.5 million Note: Each unit comprises...
Items per page:
1 - 10 of 27